Stay updated with breaking news from Acelyrin Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Acelyrin, Inc. (NASDAQ:SLRN – Free Report) – Equities researchers at HC Wainwright boosted their Q2 2024 EPS estimates for shares of Acelyrin in a report released on Wednesday, May 22nd. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share of ($0.33) for the quarter, up from their previous estimate […]
Acelyrin, Inc. (NASDAQ:SLRN – Get Free Report) reached a new 52-week low during trading on Wednesday . The company traded as low as $5.61 and last traded at $5.67, with a volume of 81890 shares changing hands. The stock had previously closed at $5.95. Wall Street Analysts Forecast Growth A number of research analysts have […]
Acelyrin (NASDAQ:SLRN – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued to clients and investors on Monday, Benzinga reports. They currently have a $28.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 328.13% from the company’s previous […]
Reported positive Phase 1/2 proof-of-concept data for lonigutamab, first subcutaneous anti-IGF-1R to demonstrate clinical responses in thyroid eye disease patients Achieved primary endpoint with high...
Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc.Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026Executed private placement financing of up to